Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.54 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.48 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28596707 | 0.80 | CYP2A6 (0.44) | TGFBR1 | |
| SCHEMBL18573213 | 0.79 | TRPV1 (0.71) | TRPV1PTPN1PTPN2KCNK3KCNK9 | |
| SCHEMBL14082180 | 0.79 | TRPV1 (0.75) | TRPV1PTPN1PTPN2KCNK3KCNK9 | |
| SCHEMBL10592252 | 0.76 | KCNK9 (0.57) | PTPN1KCNK3KCNK9 | |
| SCHEMBL18573396 | 0.76 | TRPV1 (0.71) | TRPV1PTPN1PTPN2KCNK3KCNK9 | |
| SCHEMBL11412882 | 0.75 | KMT2A (0.63) | PTPN1 | |
| SCHEMBL14313610 | 0.75 | TRPV1 (0.72) | TRPV1PTPN1PTPN2 | |
| SCHEMBL14082181 | 0.75 | TRPV1 (0.76) | TRPV1PTPN1PTPN2 | |
| SCHEMBL10452121 | 0.75 | TRPV1 (0.76) | TRPV1PTPN1PTPN2 | |
| SCHEMBL16026593 | 0.74 | KDM4E (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099442-B1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS INC (US) | 2014-11-19 | — | — | EP | disclosed |
| EP-2626067-A1 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | PHARMACYCLICS, INC. (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2099442-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008082856-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2008-07-10 | — | — | WO | disclosed |